EUCTR2006-005145-11-PT进行中（未招募）不适用
Estudo aleatorizado, em dupla ocultação, controlado por placebo, em grupo paralelo com vardenafil 10 mg duas vezes por dia para avaliar o efeito nas urodinâmicas em doentes com Bexiga Hiperactiva (hiperactividade do detrusor)Randomized, double-blind, placebo-controlled, parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity).
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 481
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients aged =18 years. Women must either be aged = 55 years
- •being menopausal since at least 12 months, or must use an adequate birth control
- •method (Note: as adequate method of birth control hormonal contraception,
- •sterilization, spiral/IUD or sexual abstinence is recommended. Furthermore, doublebarrier
- •methods consisting of two of the following measures may be considered at
- •the discretion of the investigator: male or female condom with spermicidal gel,
- •diaphragm, sponge, cervical cap).
- •Diagnosis of Overactive Bladder (OAB), with and without urge incontinence, for at least six months prior to Visit 1
- •At least one out of the three criteria below (to be assessed at Visit 2):
- •* Entire bladder capacity (= maximum cystometric bladder capacity) = 300 mL.
- •* In accordance with ICS-guidelines: Detrusor overactivity as defined as
- •spontaneous involuntary detrusor contraction during filling phase
- •*Detrusor contraction during filling phase leading to involuntarily initiated
- •micturition before a normal bladder capacity is reached.
- •Symptoms of OAB are to be assessed during the unmedicated run-in by a 7-day
- •micturition diary (in-between Visits 1 and 2).
- •* Each patient must show on average over all days documented:
- •- at least 8 micturitions per day and
- •-at least 1 urgency episode per day
- •* Each patient must document a minimum of 3 consecutive days out of 7 days.
- •Patients capable of understanding the given information and having signed and dated written Patient Informed Consent Form after full discussion of the research nature of the treatment and its risks and benefits
- •Patients able to swallow the study medication in accordance with the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Conc. Medic.
- •Treat. with drugs known to affect urinary bladder function (e.g. anticholinergics, antispasmodics, serotonin-noradrenalin-reuptake-inhibitors) 21 d. prior to V.2 and at any time during study
- •Treat. with solifenacin 28 d. prior to V. 2 and at any time during study
- •Treat. with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to V. 2 and at any time during study
- •Use of cholinergic agonists and cholinesterase inhibitors, e.g. bethanecol, donepezil, rivastigmine
- •Subj. who are taking nitrates or nitric oxide donors
- •Use of PDE5 inhibitors within 7 d. prior to V.1
- •Pts on alpha-blockers
- •Subj. who are taking the following potent inhibitors of cytochrome P450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin or clarithromycin.
- •Treat. with acenocumarol or heparin.
- •Treat. with drugs known to prolong the QT interval, eg Class IA (eg quinidine,
- •procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications
- •Treat. with androgens
- •Previous or Current Med.Cond. - General
- •Any unstable med., psychiatric, or substance abuse disorder that in the opinion of the Inv. is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study
- •Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION)
- •Hereditary degenerative retinal disorders such as retinitis pigmentosa
- •Any severe CV condition including unstable angina pectoris and severe
- •myocardial insufficiency defined as stages III or IV according to the classification of
- •the NY Heart Association (NYHA)
- •History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months.
- •Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate = 100 bpm).
- •Resting hypotension (a resting systolic blood pressure of < 90 mmHg) or hypertension (a resting systolic blood pressure > 170 mmHg or a resting diastolic blood pressure > 110 mmHg).
- •Symptomatic postural hypotension within 6 months of V.1
- •History of positive test for Hep. B surface antigen (HBsAg) or Hep. C.
- •Significant active peptic ulceration
- •Severe chronic or acute liver disease, history of moderate (Child-PughB) or severe (Child-Pugh C) hepatic impairment
- •In men: Clinically significant chronic haematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma and leukemia
- •History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- •Bleeding disorder
- •Pts with congenital QT prolongation
- •Pts with left ventricular outflow obstruction, e.g.due to an Aortic valve disorder
- •Prev. or Current Medical Condit. – Urinary Tract
- •Bladder fibrosis (low compliance and detru. hyporeflexia/hypocontractility), detru.-sphincter-dyssynergia, detru. hyporeflexia/areflexia and bradykinesia/tremor of the external urethral sphincter
- •Males with post-void residual (PVR) urinary volume >150 mL at Baseline
- •Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator
- •Chronic persistent local pathology that in the opinion of the inv. may lead to urinary symptoms, such as one of the genito-urinary pain syndromes, interstitial cystitis
- •Unexplained
研究者
相似试验
进行中（未招募）
不适用
Estudio aleatorizado, a doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de AMG 827 en sujetos con enfermedad de Crohn de moderada a grave / A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn's DiseaseCrohn's disease / Enfermedad de CrohnMedDRA version: 12.1Level: LLTClassification code 10011408Term: Crohns disease aggravatedEUCTR2010-019544-39-ESAmgen Inc216
进行中（未招募）
不适用
Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía oral tres veces al día (TID) como tratamiento adyuvante en pacientes con crisis convulsivas de comienzo parcial resistentes al tratamientoepilepsiaMedDRA version: 12.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2010-018766-23-ESovartis Farmacéutica S.A57
进行中（未招募）
1 期
Estudio aleatorizado, en doble ciego y controlado con placebo, de la eficacia y la seguridad de TAK-242 frente al placebo en sujetos con insuficiencia cardiovascular y respiratoria inducida por sepsisA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety ofTAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory FailureShock séptico e insuficiencia respiratoriaSeptic shock and respiratory failure.MedDRA version: 9.1Level: PTClassification code 10040070Term: Septic shockMedDRA version: 9.1Level: PTClassification code 10038695Term: Respiratory failureEUCTR2007-005687-27-ESTakeda Global Research & Development Centre (Europe), Ltd.2,500
进行中（未招募）
不适用
Estudio aleatorizado, en doble ciego y controlado con placebo de una dosis fija de metilnaltrexona subcutánea en adultos con enfermedad avanzada y estreñimiento inducido por opiáceos: eficacia, seguridad y cuestionarios de salud adicionalesA Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health OutcomesPacientes con enfermedad avanzada y estreñimiento inducido por opiáceosOpioid-induced constipation in subjects with advanced illnessMedDRA version: 9.1Level: LLTClassification code 10010774Term: ConstipationEUCTR2007-000854-30-ESWyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs500
进行中（未招募）
不适用
Estudio aleatorizado, doble ciego y controlado sobre la eficacia de la albúmina y manitol en el cebado del sistema de circulación extracorpórea en cirugía cardiaca para reducir el sangrado postoperatorio y las necesidades transfusionalesA randomized, double-blind, controlled trial on efficacy of priming the cardiopulmonary bypass with albumin and mannitol to reduce postoperative bleeding and transfusional requirementsEUCTR2008-008009-23-ESServicio de Anestesia-Reanimación134